Neurology

Mouse studies suggest the small molecule FLT3 inhibitor BDT001 could help treat peripheral neuropathy. In one mouse model of nerve injury-induced and two mouse models of chemically-induced peripheral neuropathy, FLT3 knockout decreased mechanical hypersensitivity and pain-related behaviors compared with normal FLT3 expression. In one of the chemical-induced models and the nerve injury model, shRNA or intrathecal siRNA-mediated knockdown of FLT3, respectively, decreased hypersensitivity and pain-related behaviors compared with control shRNA or siRNA. In the same two models, BDT001 decreased pain-related behaviors and hypersensitivity compared with vehicle and in the nerve injury model, with a longer duration than pregabalin. Next steps by Biodol Therapeutics include Phase I testing of BDT001 to treat peripheral nerve pain planned for 2020.

Pregabalin, a generic GABA A receptor agonist, is marketed for neuropathic pain, epilepsy, fibromyalgia and other neurological indications...